DXCM
Dexcom Inc.
Price performance
Sep 18, 2026About
Company activity
33 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 6d | DXCM | 8-K | Dexcom Promotes Jereme Sylvain to Chief Operating Officer | — | — | — |
| 09/10 | DXCM | 8-K | DexCom Appoints Glenn Boehnlein to Board of Directors | — | — | — |
| 07/30 | DXCM | 8-K | DexCom Reports Strong Q2 2026 Financial Results and Raises Guidance | — | — | — |
| 05/28 | DXCM | 8-K | DexCom, Inc. Announces Results of 2026 Annual Meeting of Stockholders | — | — | — |
| 05/14 | DXCM | 8-K | DexCom Announces Investor Day Insights and New Share Repurchase Program | — | — | — |
| 04/30 | DXCM | 8-K | DexCom Reports Strong Q1 2026 Financial Results and Raises Guidance | — | — | — |
| 03/02 | DXCM | 8-K | DexCom CEO Retires and Transitions to Executive Chairman Role | — | — | — |
| 02/26 | DXCM | 8-K | DexCom Appoints Rick Osterloh to Board of Directors | — | — | — |
| 02/12 | DXCM | 8-K | DexCom Reports Strong 2025 Financial Results and Strategic Achievements | — | — | — |
| 01/12 | DXCM | 8-K | Dexcom Reports Preliminary Q4 and FY 2025 Results, Provides FY 2026 Outlook | — | — | — |
| 12/22/25 | DXCM | 8-K | DexCom Appoints New CEO Jacob S. Leach Effective January 1, 2026 | — | — | — |
| 10/30/25 | DXCM | 8-K | DexCom Reports Strong Q3 2025 Financial Results and Updates Guidance | — | — | — |
| 10/27/25 | DXCM | 8-K | Dexcom Appoints Dr. Euan Ashley to Board of Directors | — | — | — |
| 09/15/25 | DXCM | 8-K | DexCom CEO Takes Temporary Medical Leave, Interim Appointments Made | — | — | — |
| 07/30/25 | DXCM | 8-K | DexCom Announces Strong Q2 2025 Results and CEO Succession Plan | — | — | — |
| 05/13/25 | DXCM | 8-K | DexCom Promotes Jake Leach to President and COO | — | — | — |
| 05/09/25 | DXCM | 8-K | DexCom Appoints Renée Galá to Board and Key Committees | — | — | — |
| 05/09/25 | DXCM | 8-K | DexCom Announces Amendments to Equity Incentive Plan and Election of Board Members | — | — | — |
| 05/02/25 | DXCM | 8-K | DexCom Director Karen Dahut Resigns from Board | — | — | — |
| 05/01/25 | DXCM | 8-K | DexCom Announces Q1 2025 Financial Results and $750M Share Repurchase Program | — | — | — |
| 03/25/25 | DXCM | 8-K | DexCom, Inc. Announces Change in Independent Registered Public Accounting Firm | — | — | — |
| 03/10/25 | DXCM | 8-K | Dexcom Appoints Renée Galá to Board of Directors | — | — | — |
| 03/07/25 | DXCM | 8-K | FDA Warning Letter Received by DexCom, Inc. | — | — | — |
| 02/13/25 | DXCM | 8-K | DexCom Reports 2024 Financial Results and Strategic Highlights | — | — | — |
| 01/13/25 | DXCM | 8-K | DexCom Reports Fourth Quarter 2024 and Fiscal Year 2024 Preliminary Results | — | — | — |
| 12/23/24 | DXCM | 8-K | DexCom and Abbott Settle Patent Litigation with Cross-Licensing Agreement | — | — | — |
| 10/24/24 | DXCM | 8-K | DexCom Reports Q3 2024 Financial Results with Revenue Growth and Strategic Highlights | — | — | — |
| 07/25/24 | DXCM | 8-K | DexCom Reports Q2 2024 Financial Results and Announces Share Repurchase Program | — | — | — |
| 05/24/24 | DXCM | 8-K | DexCom, Inc. Announces Voting Results from 2024 Annual Meeting of Stockholders | — | — | — |
| 04/25/24 | DXCM | 8-K | DexCom Reports Strong Q1 2024 Financial Results and Strategic Advancements | — | — | — |
| 02/15/24 | DXCM | 8-K | DexCom, Inc. Terminates Outstanding Warrants with Bank of America | — | — | — |
| 02/08/24 | DXCM | 8-K | DexCom Reports Strong Q4 2023 Financial Results and Strategic Highlights | — | — | — |
| 01/08/24 | DXCM | 8-K | DexCom Announces Preliminary FY 2023 Revenue and FY 2024 Outlook | — | — | — |
DXCM filing record
Dexcom Inc. (DXCM): 33 8-K filings summarized, the most recent on Sep 14, 2026.
What the 8-K filings said
- Sep 14, 2026 · high impact
On September 14, 2026, DexCom, Inc. announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer (CFO). In this expanded role, Mr. Sylvain will assume oversight of Dexcom's global operations and quality teams, driving greater alignment…
Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Sep 10, 2026 · high impact
On September 10, 2026, DexCom, Inc. announced the appointment of Glenn Boehnlein to its Board of Directors, effective immediately. Mr. Boehnlein, a seasoned healthcare executive and former CFO of Stryker Corporation, brings extensive experience in financial leadership, strategic M&A, and operational excellence. He was…
DexCom Appoints Glenn Boehnlein to Board of Directors - Jul 30, 2026 · high impact
DexCom, Inc. reported a 13% year-over-year increase in revenue for the second quarter of 2026, reaching $1.308 billion. The company also announced positive results from the CONNECT trial and the launch of the Stelo app. DexCom raised its fiscal year 2026 revenue guidance to $5.18 - $5.25 billion, reflecting an…
DexCom Reports Strong Q2 2026 Financial Results and Raises Guidance - May 28, 2026 · medium impact
DexCom, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026. Stockholders elected twelve new directors, ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm, and approved the compensation of named executive officers on a non-binding advisory basis.
DexCom, Inc. Announces Results of 2026 Annual Meeting of Stockholders - May 14, 2026 · medium impact
On May 14, 2026, DexCom, Inc. held its 2026 Investor Day in Mesa, Arizona, where it discussed market opportunities, business strategy, innovation efforts, and long-term financial outlook. The company also announced new long-range financial targets, including organic revenue growth of 10%+ annually through 2030, and a…
DexCom Announces Investor Day Insights and New Share Repurchase Program
SEC filings in the last five years
- 54 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A